0.535
-0.03 (-4.62%)
| Penutupan Terdahulu | 0.561 |
| Buka | 0.559 |
| Jumlah Dagangan | 285,806 |
| Purata Dagangan (3B) | 366,604 |
| Modal Pasaran | 30,221,422 |
| Harga / Buku (P/B) | 1.78 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Nov 2025 |
| EPS Cair (TTM) | -0.960 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.67% |
| Nisbah Semasa (MRQ) | 3.00 |
| Aliran Tunai Operasi (OCF TTM) | -15.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -15.19 M |
| Pulangan Atas Aset (ROA TTM) | -90.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -332.67% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | TuHURA Biosciences, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 2.50 |
|
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 41.96% |
| % Dimiliki oleh Institusi | 8.43% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Apollon Wealth Management, Llc | 31 Dec 2025 | 134,293 |
| Suncoast Equity Management | 30 Sep 2025 | 104,409 |
| Sabal Trust Co | 31 Mar 2025 | 39,427 |
| Hurlow Wealth Management Group, Inc. | 30 Sep 2025 | 31,444 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (HC Wainwright & Co., 1,768.81%) | Beli |
| Median | 9.00 (1,581.93%) | |
| Rendah | 8.00 (Maxim Group, 1,395.05%) | Beli |
| Purata | 9.00 (1,581.93%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 1.26 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 03 Feb 2026 | 10.00 (1,768.81%) | Beli | 0.467 |
| 09 Jan 2026 | 10.00 (1,768.81%) | Beli | 0.754 | |
| Maxim Group | 14 Nov 2025 | 8.00 (1,395.05%) | Beli | 2.05 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |